


Telaglenastat

Chemical Properties

CAS No. :	1439399-58-2
Formula:	C ₂₆ H ₂₄ F ₃ N ₇ O ₃ S
Molecular Weight:	571.57
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Telaglenastat (CB 839) (IC ₅₀ of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.
Targets(IC ₅₀)	Glutaminase, Autophagy, transporter
In vitro	CB-839 exhibits time-dependent and slowly reversible kinetics. IC ₅₀ values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for 1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor-positive cell line, T47D.[1]
In vivo	In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.[1]
Kinase Assay	Inhibition of CB-839 on rHu-GAC: The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K ₂ HPO ₄ , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP ⁺ and 0.01% Triton X-100. To measure inhibition, the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (μM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitors the conversion of glutamate (1 to 75 μM) plus NADP ⁺ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 μM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10 ^{^((LogIC₅₀-X)*HillSlope))}).
Cell Research	For viability assays, all cell lines are treated with CB-839 at the indicated concentrations for 72 hours and analyzed for antiproliferative effects using Cell Titer Glo.(Only for

Reference)

Solubility Information

Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9.3 mg/mL (16.27 mM), Suspension. H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 60 mg/mL (104.97 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7496 mL	8.7478 mL	17.4957 mL
5 mM	0.3499 mL	1.7496 mL	3.4991 mL
10 mM	0.175 mL	0.8748 mL	1.7496 mL
50 mM	0.035 mL	0.175 mL	0.3499 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol Cancer Ther.* 2014 Apr;13(4):890-901.
- Caiola E, Colombo M, Sestito G, et al. Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. *Cells.* 2020, 9(8): 1766
- Zhao G, Zhu H, Xue X, et al. Feline Calicivirus Infection Manipulates Central Carbon Metabolism. *Veterinary Sciences.* 2025, 12(2): 138.
- Emberley E, et al. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. *PLoS One.* 2021 Nov 3;16(11):e0259241.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481